Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 178

The DOI matches its Crossref record.

Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications.

Kwiatkowski, D J, Harpole, D H, Godleski, J, Herndon, J E, Shieh, D B, Richards, W, Blanco, R, Xu, H J, Strauss, G M, Sugarbaker, D J · 1998 · Journal of Clinical Oncology

Abstract

PURPOSE: To retrospectively construct a comprehensive multivariate model of cancer recurrence and to design a molecular pathologic substaging system in stage I non-small-cell lung cancer (NSCLC). METHODS: All patients with stage I NSCLC resected at Brigham and Women's Hospital (Boston, MA) between 1984 and 1992 with adequate clinical follow-up were studied. The importance of three demographic characteristics, surgical extent, 11 pathologic features, and seven molecular factors on cancer-free survival was examined. RESULTS: Two hundred forty-four patients were studied, with 25 noncancer deaths and 80 patients with recurrent disease. Significant univariate predictors (P < .05) of cancer recurrence were age older than 60 years, male sex, wedge resection, World Health Organization (WHO) adenocarcinoma subtype solid tumor with mucin, lymphatic invasion, and p53 expression. Multivariate analysis identified nine independent predictors of recurrence: solid tumor with mucin, a wedge resection, tumor diameter of 4 cm or greater, lymphatic invasion, age older than 60 years, male sex, p53 expression, K-ras codon 12 mutation, and absence of H-ras p21 expression. Multivariate cancer-free survival (CFS) analysis in the 180 patients who underwent lobectomy or pneumonectomy led to the elimination of sex and age, which left six independent factors. CONCLUSION: Lobectomy or pneumonectomy should be performed in stage I NSCLC. Using the six independent factors for recurrent disease, we propose a pathologic molecular substaging system. Patients with two factors or less are graded Ia, with a 5-year CFS rate of 87%; those with three factors are graded Ib, with a 5-year CFS rate of 58%; and those with four factors or more are graded Ic, with a 5-year CFS rate of 21%.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.1998.16.7.2468

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 178

Metadata

Authors
Kwiatkowski, D. J., Harpole, D. H., Godleski, J., Herndon, J. E., Shieh, D. B., Richards, W., Blanco, R., Xu, H. J., Strauss, G. M., & Sugarbaker, D. J.
Venue
Journal of Clinical Oncology
Published
1998-07
Volume
16
Issue
7
Pages
2468-2477
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2148725505
Cited by
178
References
0
FWCI
13.56
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications. https://app.cochat.ai/papers/10.1200/jco.1998.16.7.2468
The paper
Kwiatkowski, D. J., Harpole, D. H., Godleski, J., Herndon, J. E., Shieh, D. B., Richards, W., Blanco, R., Xu, H. J., Strauss, G. M., & Sugarbaker, D. J. (1998). Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1998.16.7.2468

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.